The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Short-Term Effects of Rituximab in Children with Steroid- and Calcineurin-Dependent Nephrotic Syndrome: A Randomized Controlled Trial
Open accessAbstract
Summary: Background and objectives: Prednisone and calcineurin inhibitors are the mainstay therapy of idiopathic nephrotic syndrome (INS) in children. However, drug dependence and toxicity associated with protracted use are common. Case series suggest that the anti-CD20 monoclonal antibody rituximab (RTX) may maintain disease remission. Design, setting, participants, & measurements: This open-label randomized controlled trial was powered to show that a strategy based on RTX and lower doses of prednisone and calcineurin inhibitors was noninferior to standard doses of these agents in maintaining 3-month proteinuria as low as baseline or up to 1 g/d greater (noninferiority margin). Participants were stratified by the presence of toxicity to prednisone/calcineurin inhibitors and centrally assigned to add RTX (Mabthera, 375 mg/m 2 intravenously) to lower doses of standard agents or to continue with current therapy alone. The risk of relapse was a secondary outcome. Results: Fifty-four children (mean age 11 ± 4 years) with INS dependent on prednisone and calcineurin inhibitors for >12 months were randomized. Three-month proteinuria was 70% lower in the RTX arm (95% confidence interval 35% to 86%) as compared with standard therapy arm (intention-to-treat); relapse rates were 18.5% (intervention) and 48.1% (standard arm) ( P = 0.029). Probabilities of being drug-free at 3 months were 62.9% and 3.7%, respectively ( P < 0.001); 50% of RTX cases were in stable remission without drugs after 9 months. Conclusions: Rituximab and lower doses of prednisone and calcineurin inhibitors are noninferior to standard therapy in maintaining short-term remission in children with INS dependent on both drugs and allow their temporary withdrawal.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tanner, J. M., & Whitehouse, R. H. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.3.170 · Cited by 3,137
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Boute, N., Gribouval, O., Roselli, S., Benessy, F., Lee, H., Fuchshuber, A., Dahan, K., Gubler, M.-C., Niaudet, P., & Antignac, C. (2000) · Nature Genetics · doi:10.1038/74166 · Cited by 1,444
Systemic Adverse Effects of Inhaled Corticosteroid Therapy: A Systematic Review and Meta-analysis
Lipworth, B. J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.9.941 · Cited by 918
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Idiopathic nephrotic syndrome in children
Noone, D. G., Iijima, K., & Parekh, R. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30536-1 · Cited by 586
Iijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., Miura, K., Aya, K., Nakanishi, K., Ohtomo, Y., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60541-9 · Cited by 451
Floege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
Trautmann, A., Boyer, O., Hodson, E., Bagga, A., Gipson, D. S., Samuel, S., Wetzels, J., Alhasan, K., Banerjee, S., Bhimma, R., et al. (2023) · Pediatric Nephrology · doi:10.1007/s00467-022-05739-3 · Cited by 292
Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome
Ruggenenti, P., Ruggiero, B., Cravedi, P., Vivarelli, M., Massella, L., Marasà, M., Chianca, A., Rubis, N., Ene-Iordache, B., Rudnicki, M., et al. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013030251 · Cited by 267
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Metadata
- Authors
- Ravani, P., Magnasco, A., Edefonti, A., Murer, L., Rossi, R., Ghio, L., Benetti, E., Scozzola, F., Pasini, A., Dallera, N., Sica, F., Belingheri, M., Scolari, F., & Ghiggeri, G. M.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2011-06
- Volume
- 6
- Issue
- 6
- Pages
- 1308-1315
- ISSN
- 1555-9041 (ISSN-L)
- OpenAlex
- W2106387428
- Cited by
- 207
- References
- 4
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.